← Back to headlines
Inovio targets October 30 PDUFA date for INO-3107 approval while extending cash runway into Q4 2026
Inovio Pharmaceuticals Inc. (NASDAQ: INO) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational DNA medicine INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP).
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
